New drug CLYM116 enters first human safety trial
NCT ID NCT07248865
First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 27 times
Summary
This early-stage study tests the safety of a new drug, CLYM116, in 48 healthy adults aged 18-60. Participants receive either the drug or a placebo by injection, and researchers monitor for side effects and how the drug moves through the body. The study is not designed to treat any disease, but to gather essential safety data before testing in patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nucleus Network Brisbane
RECRUITINGBrisbane, 4006, Australia
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CLYM116
What could go wrong
This is a very early Phase 1 study in healthy people, so it cannot show if the drug works for any disease. The main goal is safety, not effectiveness.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.